In a patient with a recent small‑to‑moderate left parietal ischemic stroke who has not yet received antiplatelet therapy, should antiplatelet medication be started now or wait until a direct oral anticoagulant (DOAC) is initiated?

Start Antiplatelet Therapy Immediately—Do Not Wait for DOAC Initiation

In a patient with a recent small-to-moderate left parietal ischemic stroke who has not yet received antiplatelet therapy, you should start aspirin 160-300 mg immediately, then transition to DOAC within 2-14 days based on stroke severity and hemorrhagic risk. Do not leave the patient unprotected while waiting to start anticoagulation.

Rationale for Immediate Antiplatelet Therapy

The evidence strongly supports immediate antiplatelet therapy in acute ischemic stroke. Aspirin 160-300 mg started within 48 hours of stroke onset significantly reduces death and dependency (OR 0.95% CI 0.91-0.99), preventing death or dependency in 13 per 1000 patients treated 1. This benefit comes from reducing early recurrent ischemic stroke by 7 events per 1000 patients, with only a minimal increase of 2 symptomatic intracranial hemorrhages per 1000 patients 2.

The critical window is within 48 hours of symptom onset—your patient has already missed antiplatelet therapy and should receive it now rather than remaining unprotected.

Timing Algorithm for Transition to DOAC

Once aspirin is started, the transition to DOAC follows this evidence-based timeline 3:

For Small-to-Moderate Stroke (Your Patient):

• Low hemorrhagic risk: Initiate DOAC 2-14 days after the index event 3
• Recent evidence supports earlier initiation: Within 4 days for minor-to-moderate strokes to prevent new vascular events 4
• Optimal approach: Start aspirin immediately, then transition to DOAC within 4-7 days

For TIA:

• Initiate anticoagulation immediately after the index event 3

For Large Stroke with High Hemorrhagic Risk:

• Delay DOAC initiation beyond 14 days to reduce ICH risk 3

Key Management Points

Anticoagulation is superior to antiplatelet therapy for AF-related stroke. The AHA/ASA guidelines give Class I, Level A recommendation for DOACs (apixaban, dabigatran, edoxaban, rivaroxaban) over warfarin in nonvalvular AF 3. DOACs reduce recurrent stroke risk more effectively than aspirin alone.

Do not continue dual therapy. Once DOAC is initiated, discontinue aspirin. There is no evidence supporting combined antiplatelet-anticoagulant therapy for secondary stroke prevention in AF, and this increases bleeding risk without additional benefit 5.

Common Pitfalls to Avoid

• Leaving the patient unprotected: The highest risk of recurrent stroke is in the first few days. Starting aspirin immediately provides some protection during the vulnerable period before DOAC initiation
• Starting DOAC too late in moderate stroke: Recent evidence suggests 4-day initiation is safe and potentially more effective than delayed treatment 4
• Continuing aspirin after DOAC initiation: This unnecessarily increases bleeding risk
• Using high-intensity anticoagulation: INR 3.0-4.5 increases major bleeding 9-fold and should never be used 5

Practical Implementation

1. Today: Start aspirin 160-300 mg orally (or per rectum/NG tube if unable to swallow) 1
2. Days 1-3: Monitor for hemorrhagic transformation with clinical assessment ± imaging if indicated
3. Day 4-7: Initiate DOAC (apixaban, dabigatran, edoxaban, or rivaroxaban preferred over warfarin 3) and discontinue aspirin
4. If high hemorrhagic risk identified: Extend aspirin therapy and delay DOAC to day 14+

This approach balances immediate stroke recurrence prevention with the superior long-term protection offered by anticoagulation in AF-related stroke.